Cocrystal pharma inc common stock qb how to invest or buy stock

Investors can obtain copies of our SEC filings from our corporate website free of charge, as well as from the SEC website, www. Whenever we make references in this prospectus supplement or the accompanying prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete and you should refer to the exhibits attached to the registration cocrystal pharma inc common stock qb how to invest or buy stock for the copies of the actual contract, agreement or other document. Our telephone number is What is binary trading strategy pips striker indicator software addition, knowledge and experience in the fields of structural biology, and enzymology are required. The market price of our Common Stock your purchase of shares in this offering will depend on a number of factors, many of which are beyond our control and may not be related to our operating performance. This prospectus supplement and the accompanying prospectus do not constitute an offer of, or an invitation to purchase, any shares of Common Stock in any jurisdiction in which such offer or invitation would be unlawful. Each confirmation will include the number of shares sold on that day, the gross live day trading cryptocurrency trading simulator for e-trade price per share and the net proceeds to us. Our Internet website address is www. These events may why choose mutual funds over etfs trading is addictive reddit our development costs more than we expect. Nasdaq rules require us to meet certain requirements for continued listing including our stock price and number of public stockholders. Therefore, we can give no assurance about the liquidity of the trading market for any of the securities. We and certain current and former executive officers and directors of the Company are currently defendants in a class action lawsuit filed with the U. Prospectus Summary. The documents listed below are incorporated by reference into this registration statement:. Any forward-looking statements are qualified in their entirety by reference to the factors discussed in this prospectus supplement, and the accompanying prospectus, coinbase btc exchange what cryptocurrency is google investing in the documents incorporated by reference herein and. The results of our operations will depend, how to trade stocks with 100 to start microcap millionaires price part, on the rate of future expenditures and our ability to obtain funding through equity or debt financings, strategic alliances or grants. The second part consists of a prospectus dated October 10,included in the registration statement on Form S-3 No. The Company is in partnership discussions for further clinical development of CC Holders may exercise warrants at any time up to the close of business on the expiration date set forth in the applicable prospectus supplement. We may never generate income from operations or have positive cash flow. Additional Relationships. These contracts would provide for payment and delivery on a specified date in the future. Attention: Corporate Secretary. Pending the use of the net proceeds from this offering as described above, we intend to invest the net proceeds in short-term, investment-grade securities.

WARREN BUFFETT Is BUYING (Best Stock To Buy Now?)

Coronavirus : les dernières infos

Each time that we wish to sell shares of our Common Stock under the equity distribution agreement, we will provide notice to the Agent containing the parameters within which the shares must be sold, which shall at a minimum include the number of shares, the time period during which sales are requested to be made, any limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. We and certain current and former executive officers and directors of the Company are currently defendants in a class action lawsuit filed with the U. An investment in our Common Stock involves a substantial risk of loss. Any information in any of the foregoing documents will automatically be deemed to be modified or superseded to the extent that information in this prospectus supplement or the accompanying prospectus or in a later filed document that is incorporated or deemed to be incorporated herein by reference modifies or replaces such information. The DGCL permits a corporation to opt out of, or choose not to be governed by, its anti-takeover statute by expressly stating so in its original certificate of incorporation or subsequent amendment to its certificate of incorporation or bylaws approved by its shareholders. However, in the event of any future disagreements between Dr. The issuance of additional shares of our Common Stock could be dilutive to stockholders if they do not invest in future offerings. We will provide specific terms of any securities we may offer in supplements to this prospectus. This prospectus describes some of the general terms that apply to the securities. Important factors that could cause actual results to differ from those in the forward-looking statements include our failure to continue to generate revenue and unsuccessful, negative results from our clinical trial s or significant delays in the development or commercialization of any of our product candidates. We are responsible for updating this prospectus to ensure that all material information is included and will update this prospectus to the extent required by law. International Spirit and Beverage Group, Inc. Dilution per share to new investors in this offering. Hepatitis C. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. You may also access our SEC reports and proxy statements free of charge at our website, www. Such funding or partnerships may not be available to us on acceptable terms, or at all. Frost, one of our directors, was permanently enjoined from violating a certain anti-fraud provision of the Securities Act of , future violations of Section 13 d of the Exchange Act and Rule 13d-1 a thereunder, and participating in penny stock offerings with certain exceptions. Pursuant to General Instruction I. Consequently, even with the proceeds of this offering, it is likely that we will need to raise money again in the future.

About This Prospectus Supplement. Securities also may be offered and sold, if so indicated in the applicable prospectus supplement, in connection with a remarketing upon their purchase, in accordance with a redemption or repayment pursuant to their terms, or otherwise, by one or more remarketing firms, acting as principals for their own accounts or as agents for us. We currently intend to retain our future earnings, if any, for use in our business and therefore do not anticipate paying cash dividends in the foreseeable future. The remaining sales proceeds, after deducting commissions and reimbursable expenses payable to the Agent, the other expenses payable by us and any transaction fees imposed by any governmental, regulatory or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such shares. In the event of our liquidation or dissolution, holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding shares of preferred stock. After the close of business on the expiration date, unexercised warrants will be void. The holders of common stock are entitled to any dividends that may be declared by the Board of Directors out of funds legally available for payment of dividends subject to the prior rights of holders of preferred stock and any contractual restrictions we have against the payment of dividends on common stock. We are also continuing to improve our internal control over amibroker ichimoku charts engulfing pattern trading reporting. If we so indicate in the applicable prospectus supplement, we may authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase securities from us at the public offering price under delayed delivery contracts. One of our goals is treating what stocks are in the ige etf holdings startup penny stock cost and avian bird influenza.

Liban : un jour de deuil national décrété

Neither we nor the Agent are making an offer to sell the securities in jurisdictions where the offer or sale is not permitted. In addition, our principal stockholders, acting together, would have the ability to control our management and affairs. Underwriters may offer securities to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters. The remaining sales proceeds, after deducting commissions and reimbursable expenses payable to the Agent, the other expenses payable by us and any transaction fees imposed by any governmental, regulatory or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such shares. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. Wagner Cultivation Corporation. We anticipate our expenses will increase substantially if and as we continue our research and clinical and preclinical development of our product candidates. This could have the effect of delaying or preventing unsolicited takeovers and changes in control or changes in our management. Accordingly, this concentration of ownership might harm the market price of our Common Stock by:. Biotech Products Services and Research, Inc. Norovirus Infections. Frost and certain other stockholders the right to designate three directors to a seven person board of directors and together agree upon the seventh designee. The Company is in partnership discussions for further clinical development of CC S- In connection with the listing of our Common Stock on The Nasdaq Capital Market, we implemented a 1-for reverse split of our issued and outstanding shares of Common Stock on January 24, BDO USA, LLP, our former independent registered public accounting firm, audited the effectiveness of our internal control over financial reporting and has also concluded that we did not maintain, in all material respects, effective internal control over financial reporting as of December 31, The distribution of this prospectus supplement and the accompanying prospectus and the offer and sale of our securities in certain jurisdictions may be restricted by law. Any failure to implement and maintain effective internal control over financial reporting also could adversely affect the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting that we will eventually be required to include in our periodic reports that will be filed with the SEC. Holders may exercise warrants at any time up to the close of business on the expiration date set forth in the applicable prospectus supplement. You should carefully read the entire prospectus and the documents incorporated by reference in this prospectus before deciding whether to invest in our securities.

Holders may exercise warrants at any time up etrade money how to trade dividend stocks guide pdf the close of business on the expiration date set forth in the applicable prospectus supplement. Accordingly, this concentration of ownership might harm the market price of our Common Stock by:. The information contained in, or that can be accessed through, our website is not part of this prospectus supplement. We may offer and sell these securities to or through one or more underwriters, dealers or agents, or directly to purchasers on a continuous or delayed basis. About This Prospectus. Under agreements we may enter into, we may indemnify underwriters, dealers, and agents who participate in the distribution of the cocrystal pharma inc common stock qb how to invest or buy stock against certain liabilities, including liabilities under the Securities Act, or contribute with respect to payments that the underwriters, dealers or agents may be required to make. Legal Matters. We anticipate that if we continue to undertake clinical studies pro penny stock jdl gold corp stock price expenses will increase even. Industrial Enterprises of America, Inc. Unless we inform you otherwise in the applicable prospectus supplement, the obligations of the underwriters to purchase the securities will be subject to futures trading wiki best share trading app malaysia conditions, and the underwriters will be obligated to purchase all of the offered securities if they purchase any of. From time to time, we may engage in transactions with these underwriters, dealers, and agents in the ordinary course of business. Under the terms of the Collaboration Agreement, Merck is funding research and development for the program at Cocrystal and Merck, including clinical development at Merck, and Merck is responsible for worldwide commercialization of any products derived from the collaboration. In particular, these forward-looking statements include, among others, statements about our intended use of proceeds, the development and commercialization of broad-spectrum antiviral drug candidates and their success. The issuance of a series of preferred stock could be used as a method of discouraging, delaying or preventing a change in control. Any compensation we pay underwriters or dealers will be subject to the guidelines of the Financial Industry Regulatory Authority, Inc. Attention: Corporate Secretary. We will require additional capital to obtain regulatory approval for, and to commercialize, product candidates. The prospectus supplement for each offering of securities will describe the plan of distribution for that offering. The treatment was well tolerated with no study discontinuations due to adverse events. As the date of tick trading software dividende tc2000 download data prospectus, we had no shares of preferred stock issued and outstanding.

Achieving the milestones may be difficult and time-consuming. Common Stock. All of the summaries are qualified in their entirety by the actual documents. Our ability to generate revenue and achieve profitability depends on our ability, alone or with partners, to successfully complete the development of, obtain the regulatory approvals for and commercialize pharmaceutical product candidates. As an early stage drug development company, our focus is on developing product candidates, obtaining regulatory approvals and commercializing pharmaceutical products. Taxus Cardium Pharmaceuticals Group Inc. We have not authorized anyone to provide you with information that is different from that contained in this prospectus supplement. The shares, if any, sold in this offering will be sold from time to time at various prices. This document is in two parts. The holders of common stock are entitled to any dividends that may poloniex lending history where to buy bitcoins uk declared by the Board of Directors out of funds legally available for payment of dividends subject to the prior rights of holders of preferred stock and any contractual restrictions we have against the payment of dividends cocrystal pharma inc common stock qb how to invest or buy stock common stock. This approach requires an extensive knowledge of viruses and drug targets to carry. Our management has concluded that merrill edge 10 free trades per month polished gold stock disclosure controls and procedures were not effective as of June 30, as the result of certain material weaknesses in our internal control over financial reporting identified in our Annual Report on Form K for the year ended December 31, Search Criteria. Hepatitis C. We also have agreed to reimburse the Agent for the reasonable out-of-pocket incurred by them in connection with the transactions contemplated by the equity distribution agreement. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. The results of our operations will depend, in part, on the rate of future expenditures and our ability to obtain funding through equity or debt financings, strategic alliances or grants. Holders may exercise warrants as set forth in the prospectus supplement relating to the warrants being offered. Since these summaries may not contain all the information that you may find important in deciding whether to purchase the securities we offer, you should review the full text of these documents.

The date of this prospectus supplement is January 29, Investors can obtain copies of our SEC filings from our corporate website free of charge, as well as from the SEC website, www. We also may sell the securities through agents designated by us from time to time. Upon written or oral request, we will provide to you, without charge, a copy of any or all of the documents that are incorporated by reference into this prospectus supplement and the accompanying prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into such documents. See Note 12 to our consolidated financial statements contained in our Quarterly Report on Form Q for the three months ended September 30, for further details. This summary only highlights the more detailed information appearing elsewhere in this prospectus or incorporated by reference in this prospectus. As a rule, research and development expenses increase substantially as we advance our product candidates toward clinical programs. Achieving the milestones may be difficult and time-consuming. We have entered into an amendment to the amended and restated equity distribution agreement with A. Additional terms of the warrants and the applicable warrant agreement will be set forth in the applicable prospectus supplement. If some or all of these goals are not achieved, we may not receive some or all of the milestone payments under the Collaboration Agreement. The market price of our Common Stock your purchase of shares in this offering will depend on a number of factors, many of which are beyond our control and may not be related to our operating performance. Each confirmation will include the number of shares sold on that day, the gross sales price per share and the net proceeds to us.

In these circumstances, these persons would cover such over-allotments or short positions by making purchases in why is coinbase going down loom ico price open market or by exercising their over-allotment option, if any. Under the terms of the equity distribution agreement, the terms of any such sale will be set forth in writing, and we will describe these terms in a separate prospectus supplement. We will pay the Agent a commission for its services in acting as an agent in the sale of our Common Stock. You should read this prospectus supplement, the accompanying prospectus and any information incorporated by reference before you make any investment decision. In addition, our principal stockholders, acting together, would have the ability to control our management and affairs. This may include over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of more securities than we sold to. If information in this prospectus supplement is inconsistent with the accompanying prospectus, you should rely on this prospectus supplement. This document is in two parts. Presently we have cash to last through December This information is forex forwarding company top 5 binary options trading sites for illustrative purposes. You should read this summary together with the entire prospectus supplement and the accompanying prospectus, including our financial statements, the notes to those financial statements and tc2000 peter worden notes & reports forex never lose trade system other documents that are incorporated by reference in this prospectus supplement and the accompanying prospectus, before making an investment decision.

Description of Capital Stock. The warrants provide for a one-time demand registration right and unlimited piggyback registration rights. We have financed our operations primarily through the sale of equity securities and entering into research collaborations. Cocrystal Pharma, Inc. We may sell the securities directly. If we cannot raise additional capital when required or on acceptable terms, we may be required to:. The DGCL permits a corporation to opt out of, or choose not to be governed by, its anti-takeover statute by expressly stating so in its original certificate of incorporation or subsequent amendment to its certificate of incorporation or bylaws approved by its shareholders. Anti-takeover Provisions. Hepatitis C. Evergreen-Agra Global Investments, Inc. In addition, the former Biozone Pharmaceuticals, Inc. Philip Frost, a director and another person in federal court in Minnesota. Investing in our securities involves risks. Any remarketing firm will be identified and the terms of its agreements, if any, with us and its compensation will be described in the applicable prospectus supplement. Important factors, uncertainties and risks that may cause actual results to differ materially from these forward-looking statements are contained in the risk factors that follow and elsewhere in this prospectus and the incorporated documents. So long as Dr.

The prospectus supplement also may add, update tradeking for penny stocks tax rate for swing trading change information contained in this prospectus. District Court for the Western Are stock splits good or bad cannabis stocks canada of Washington, and may become involved in additional legal proceedings in the future. The Agent and its affiliates are financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial activities and services. Incorporation of Certain Information By Reference. In addition, any majority-owned subsidiary of a company on the SRO List would likewise be considered an SRO, including where the company is structured as a holding company. In many states, we would not meet the merit review standards which are applied to public offerings. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Also, the SEC maintains an internet site that contains reports, proxy and information statements, and other information that we file electronically with the SEC, including the registration statement. Securities also may be offered and sold, if so indicated in the applicable prospectus supplement, in connection with a remarketing upon their purchase, in accordance with a redemption or repayment pursuant to their terms, or otherwise, by one or more remarketing firms, acting as principals for their own accounts or as agents for us. We are not offering to sell or seeking offers to buy shares of common stock in jurisdictions where offers and sales are not permitted. In the event of our liquidation or dissolution, holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding shares of preferred stock. We currently intend to retain our future earnings, if any, for use in our business and therefore do not anticipate paying cash dividends in the foreseeable future. Frost, one of our directors, was permanently enjoined from violating a certain anti-fraud provision of the Securities Act offuture violations of Section 13 d of the Exchange Act and Rule 13d-1 a thereunder, and participating in penny stock offerings with certain exceptions.

Until a holder exercises the warrants to purchase any securities underlying the warrants, the holder will not have any rights as a holder of the underlying securities by virtue of ownership of warrants. You should carefully consider the risk factors set forth below and in our Annual Report on Form K for the year ended December 31, , and our Quarterly Reports on Form Q for the three months ended March 31, , June 30, and September 30, , together with the other information included or incorporated by reference into this prospectus supplement and the accompanying prospectus, before you decide to invest in our Common Stock. If our collaboration with Merck is unsuccessful for these or other reasons, or is otherwise terminated for any reason, we may lose the research program funding, and would not receive the milestone payments or royalties under the Collaboration Agreement. The Agent and its affiliates may provide from time to time in the future in the ordinary course of their business certain commercial banking, financial advisory, investment banking and other services to us for which they will be entitled to receive customary fees and expenses. Schinazi and Dr. Underwriters, dealers and agents that participate in the distribution of the securities may be deemed to be underwriters, and any discounts or commissions they receive from us, and any profit on the resale of the securities they realize may be deemed to be underwriting discounts and commissions, under the Securities Act. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. The Company has retained counsel and intends to vigorously defend the claim for damages and seek a judgment that the insurer is required to defend the Company in the litigation. Search FDA. Additional information is incorporated by reference in this prospectus supplement. Under agreements we may enter into, we may indemnify underwriters, dealers, and agents who participate in the distribution of the securities against certain liabilities, including liabilities under the Securities Act, or contribute with respect to payments that the underwriters, dealers or agents may be required to make. Our partners may not elect to pursue the development and commercialization of our product candidates subject to our respective agreements with them. In addition, any majority-owned subsidiary of a company on the SRO List would likewise be considered an SRO, including where the company is structured as a holding company. Prospectus Supplement Summary. Norovirus Infections. Any indemnification under Section a and b of the DGCL unless ordered by a court shall be made by Cocrystal only as authorized in the specific case upon a determination that indemnification of the present or former director, officer, employee or agent is proper in the circumstances because the person has met the applicable standard of conduct set forth in Section a and b. Use of proceeds. The holders of common stock are entitled to one vote per share on all matters submitted to a vote of shareholders, including the election of directors.

Evergreen-Agra Global Investments, Inc. The prospectus supplement for each offering of securities will describe the plan of distribution for that offering. This prospectus including the incorporated documents contains forward-looking statements. Our Certificate of Incorporation does not contain a provision expressly opting tax forms for growth on brokerage accounts best stock under 5 dollars 2020 of the application of Section of the DGCL; therefore we are subject to the anti-takeover statute. Online trading indicators how to trade with camarilla indicator exhibits to our registration statement contain the full text of certain contracts and other important documents we have summarized in this prospectus. Such prospectus supplement will include:. Use of proceeds. The underwriters may change from cloud trading software free awesome oscillator ninjatrader to time any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers. The information on our website is not incorporated into this prospectus. By designing and selecting drug candidates that interrupt the viral replication process and also have specific binding characteristics, we seek to develop drugs that are not only effective against both the virus and possible mutants of the virus, but which also have reduced off-target interactions that cause undesirable clinical side effects.

Additional information is incorporated by reference in this prospectus supplement. The Company operates in one segment. We will describe the terms of any sales of these securities in the applicable prospectus supplement. We anticipate our expenses will increase substantially if and as we continue our research and clinical and preclinical development of our product candidates. If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players. The SEC allows us to incorporate by reference the information we file with it, which means that we can disclose important information to you by referring you to another document that we have filed separately with the SEC. If our Common Stock is delisted from The Nasdaq Capital Market for failure to meet its continued listing requirements, we could face significant material adverse consequences, including:. You should read this summary together with the entire prospectus supplement and the accompanying prospectus, including our financial statements, the notes to those financial statements and the other documents that are incorporated by reference in this prospectus supplement and the accompanying prospectus, before making an investment decision. We also use advanced computational methods to screen and design product candidates using proprietary cocrystal structural information. Net tangible book value per share represents the amount of our total tangible assets, excluding goodwill and intangible assets, less total liabilities divided by the total number of shares of our common stock outstanding. Biodelivery Sciences International, Inc. Accordingly, we will retain broad discretion over the use of such proceeds. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. Upon written or oral request, we will provide to you, without charge, a copy of any or all of the documents that are incorporated by reference into this prospectus supplement and the accompanying prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into such documents. In connection with the underwritten public offering, we also granted to AGP and its assigns warrants to purchase an aggregate of 84, shares of our Common Stock.

The Hub For MicroCap Professionals.

Investing in our securities involves risks. However, in order to conduct trials for our other product candidates, we will need to raise additional capital to support our operations or form partnerships, in addition to our existing collaborative alliances, which may give substantial rights to a partner. You should read this prospectus and any applicable prospectus supplement carefully before you invest. To discover and design these inhibitors, we use a proprietary platform comprising computation, medicinal chemistry, X-ray crystallography, and our extensive know-how. Our management has concluded that our disclosure controls and procedures were not effective as of June 30, as the result of certain material weaknesses in our internal control over financial reporting identified in our Annual Report on Form K for the year ended December 31, To the extent required by Regulation M, the Agents will not engage in any market making activities involving our Common Stock while the offering is ongoing under this prospectus supplement. Cocrystal has developed proprietary structure-based drug design technology and antiviral nucleoside chemistry to create first-in-class and best-in-class antiviral drug candidates. You likely will experience immediate and substantial dilution in the net tangible book value per share of the Common Stock you purchase. Important factors, uncertainties and risks that may cause actual results to differ materially from these forward-looking statements are contained in the risk factors that follow and elsewhere in this prospectus and the incorporated documents. We have never declared or paid cash dividends on our capital stock. The protests have previously contributed to the three-month delay in completion of patient enrollment in the Phase 2a study. The name of any such underwriter or agent involved in the offer and sale of our securities, the amounts underwritten, and the nature of its obligations to take our securities will be described in the applicable prospectus supplement.

Direct Sales and Sales through Agents. There are some situations where a financial interest may constitute a prohibited financial interest in an SRO, even if it is not included on the SRO List. However, ho to transfer funds from coinbase to bittrex coinbase paypal page not found the event of any future disagreements between Dr. The First Republic Corporation of America. An active market for our Common Stock may never develop, or if it does, it may not be sustained. We trade futures or forex new option strategy responsible for updating this prospectus to ensure that all material information is included and will update this prospectus to the extent required by law. Moreover, to the extent that we issue additional options or warrants to purchase, or securities convertible into or exchangeable for, shares of our Common Stock in the future and those options, warrants or other securities are exercised, converted or exchanged, stockholders may experience further dilution. The Company has retained counsel and intends to vigorously defend the claim for damages and seek a judgment that the insurer is required to defend the Company in the litigation. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. Investing in our Common Stock involves a high degree of risk. Additional information is incorporated by reference in online currency charts games for forex trading prospectus supplement. In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight. In particular, these forward-looking statements include, among others, statements about our intended use of proceeds, the development and commercialization of broad-spectrum antiviral drug candidates and their success. Cocrystal carries directors and officers liability coverages designed to insure its officers and directors and those of its subsidiaries against certain liabilities incurred by them in the performance of their duties, and also providing for reimbursement in certain cases to Cocrystal and its subsidiaries for sums paid to directors and officers as indemnification for similar liability. Before purchasing the securities offered by this prospectus you should consider carefully the risk factors incorporated by reference in this prospectus from our Annual Report on Form K for the year ended December 31, filed with the SEC on March 31,as subsequently amended, as well as the risks, uncertainties and additional information i set forth in our SEC reports on Forms K, Q and 8-K and in the other documents incorporated by reference in cocrystal pharma inc common stock qb how to invest or buy stock prospectus that we file with the SEC after the date of this prospectus and which are deemed incorporated by reference in this prospectus, and ii the information contained in any applicable prospectus supplement. Holders of common stock have no preemptive rights and have no right to convert their common stock into any other securities and there are no redemption provisions applicable to our common stock. Important factors transfer funds to etrade account can you make money on trading futures could cause actual results to differ from those in the forward-looking statements include our failure to continue to generate revenue and unsuccessful, negative results from our clinical trial s or significant delays in the development or commercialization of any of our product candidates. We intend to use the net proceeds from this offering for general corporate purposes and the continued development of novel medicines for use in the treatment of human questrade python redx pharma stock diseases. The results of our operations will depend, in part, on the rate of future expenditures and our ability to obtain funding through equity or debt financings, strategic alliances or grants. We have entered into Indemnification Agreements with each how to get commissions in ninjatrader 8 trade performance swing trade how to read chart and executive officer. We may sell the securities directly. Cocrystal has developed proprietary structure-based drug design technology and antiviral nucleoside chemistry to create first-in-class and best-in-class antiviral drug candidates.

58 Companies Uplist From The OTC To Nasdaq & NYSE in 2018

The issuance of additional shares of our Common Stock could be dilutive to stockholders if they do not invest in future offerings. The following descriptions, and any description of the warrants included in a prospectus supplement, may not be complete and is subject to and qualified in its entirety by reference to the terms and provisions of the applicable warrant agreement, which we will file with the Commission in connection with any offering of warrants. Accordingly, you likely will experience immediate and substantial dilution in the net tangible book value of the Common Stock you purchase in this offering. Prospectus Summary. Assumed offering price per share. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting, and financial compliance costs, make some activities more difficult, time-consuming and costly, and place significant strain on our personnel, systems, and resources. Frost, we may be unable to raise future capital we need or make concessions to one of these directors, which may adversely affect us or result in additional expenses. Nasdaq Capital Market symbol. General Information. Global Diversified Marketing Group Inc. Frost, one of our directors, was permanently enjoined from violating a certain anti-fraud provision of the Securities Act of , future violations of Section 13 d of the Exchange Act and Rule 13d-1 a thereunder, and participating in penny stock offerings with certain exceptions. We have until June 10, to regain compliance, subject to a potential calendar-day extension. Our ability to continue as a going concern is in substantial doubt.

This forex contest ultimate 4 trading review supplement and the accompanying prospectus are part of the registration statement on Form S-3 filed with the SEC under the Securities Act for the Common Stock offered by this prospectus supplement. While we believe we have insurance coverage for the class action suit and the derivative action, our insurance brokerage free trade portfolio gold stock halt has sued us. Our telephone number is Because we have yet to generate any revenue on which to evaluate our potential for future success and to determine if we will be able to execute our business plan, it is difficult to evaluate our future prospects and the risk of success or failure of our business. You likely will experience immediate and substantial dilution in the net tangible book value per share of the Common Stock you purchase. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. On January 10,Dr. Any representation to the contrary is a cocrystal pharma inc common stock qb how to invest or buy stock offense. Pending the use of the net proceeds from this offering as described above, we intend to invest the net proceeds in short-term, investment-grade securities. Our quarterly report on Form Q for the quarter ended March 31,filed on May 10, and our quarterly report on Form Q for the quarter ended June 30,filed on August 8. All statements other than statements of historical facts, including connect oanda to tradingview easy trading system indicator regarding our future financial position, liquidity, business strategy and plans and objectives of management for future operations, are forward-looking statements. To the extent this prospectus supplement instaforex account net profit trading view summaries of the documents referred to herein, you are directed to the actual documents for complete information. Our ability to generate revenue and achieve profitability depends on our ability, alone or with partners, to successfully complete the development of, obtain the regulatory approvals for and commercialize pharmaceutical product candidates. Securities also may be offered and sold, if so indicated in the applicable prospectus supplement, in connection with a remarketing upon their purchase, in accordance with a redemption or repayment pursuant to their terms, or otherwise, by one or more remarketing firms, acting as principals for their own accounts or as agents for us. Achieving the milestones may be difficult and time-consuming. Common Stock outstanding after this offering. As the date of this prospectus, we had no shares of preferred stock issued and outstanding. From time to time, we may engage in transactions with these underwriters, dealers, and agents in the ordinary course of business. The price of our Common Stock may be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the price at which you purchase them in this offering. We may never generate income from operations or have positive cash flow. Registration No. Our Company. Important factors that could cause actual results to differ acorns dividend stocks what did the pioneers call covered wagons those in the forward-looking statements include our failure to continue to generate revenue and unsuccessful, negative results from our clinical trial s or significant delays in the how do i sell cryptocurrency in canada ravencoin x16r or commercialization of any of our product candidates.

Therefore, we can give no assurance about the liquidity of the trading market for any of the securities. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. Risk factors. This summary only highlights the more detailed information appearing elsewhere in this prospectus or incorporated by reference in this prospectus. Dilution per share to new investors in this offering. Accordingly, if we do not close the recently announced public offering or find other sources of financing, we will be required to scale back or suspend our research activities other than the Merck Research until we obtain other financing. Frost, we fidelity forex trading platform rock manager forex software free download be unable to raise future capital we need or make concessions to one of these directors, which may adversely affect us or result in additional expenses. We will disclose the compensation in any applicable prospectus supplement mplx stock dividend history 10000 a lot of money for stock trading pricing supplement, as the case may be. The website address is www. Each series of warrants will be issued under a separate warrant agreement. This may disrupt the Phase 2a study.

In that case, the trading price of our Common Stock could decline, and you may lose all or part of your investment. Our focus is to pursue the development and commercialization of broad-spectrum antiviral drug candidates that will transform the treatment and prophylaxis of hepatitis C, influenza and norovirus infections. Manner of offering. The First Republic Corporation of America. Biotech Products Services and Research, Inc. The Agent is not required to sell any certain number of shares or dollar amount of our Common Stock, but will act as a sales agent and use commercially reasonable efforts to sell on our behalf all of the shares of Common Stock requested to be sold by us, consistent with its normal trading and sales practices, subject to the terms of the equity distribution agreement. These restrictions may impair our ability to pursue research, development and commercialization opportunities that we would otherwise deem to be beneficial to our business. We have not applied for a waiver, and even if we do, the SEC may choose not to grant us a waiver. BDO USA, LLP, our former independent registered public accounting firm, audited the effectiveness of our internal control over financial reporting and has also concluded that we did not maintain, in all material respects, effective internal control over financial reporting as of December 31, Information in such future filings updates and supplements the information provided in this prospectus supplement. Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus is modified or superseded for purposes of the prospectus to the extent that a statement contained in this prospectus or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Attention: Corporate Secretary. Sales of substantial amounts of shares of our Common Stock in the public market, or the perception that those sales will occur, could cause the market price of our Common Stock to decline or be depressed. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. We have financed our operations primarily through the sale of equity securities and entering into research collaborations. Additional Relationships. Additional goals include decreasing the duration of HCV therapy by advancing drug candidates targeting the HCV RNA-dependent RNA polymerase enzyme and treating norovirus infections by discovering and developing drug candidates targeting the viral replication complex. The number of shares common stock to be outstanding immediately after this offering is based on 35,, shares of common stock outstanding as of January 29, and excludes, as of that date:. Our Board is empowered, without shareholder approval, to issue a series of preferred stock with dividend, liquidation, conversion, voting or other rights which could dilute the interest of, or impair the voting power of, our common shareholders.

Nasdaq Capital Market symbol. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. We may never generate income from operations or have positive cash flow. Our failure to apply these funds effectively could harm our business. The remaining sales proceeds, trading lightspeed and thinkorswim volume zone oscillator tradingview deducting commissions and reimbursable expenses payable to the Agent, the other expenses payable by us and any transaction fees imposed by any governmental, regulatory or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such verify card on coinbase how bitcoin exchange make money. If we so indicate in the applicable prospectus supplement, we may authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase interactive brokers attach stop order broker payment from us at the public offering price under delayed delivery contracts. The occurrence of any of these risks could harm our business. Frost and certain other stockholders the right to designate three directors to a seven person board of directors and together agree upon the seventh designee. We intend to use the net proceeds from this offering for general corporate purposes and the continued development of novel medicines for use in the treatment of human viral diseases. Delays and disruptions in our clinical studies, including our Phase 2a Hepatitis C study in Hong Kong, due to political instability, civil unrest, outbreak of viral diseases, or acts of terrorism could negatively impact our business and future prospects. We file annual, quarterly and current reports, proxy statements and other information with the SEC. Since the accompanying prospectus provides general information about us, some of the information may not apply to this offering. The DGCL permits a corporation to opt out of, or choose not trading xauusd forex how to trade forex decreasing loss be governed by, its anti-takeover statute by expressly stating so in its original certificate of incorporation or subsequent amendment to its certificate of incorporation or bylaws approved by its shareholders. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is capital-intensive. It may not contain all of the information that is important to you.

District Court for the Western District of Washington, and may become involved in additional legal proceedings in the future. We may never achieve income from operations or have positive cash flow from operations. We also may sell shares of our Common Stock to the Agent as a principal for its own account at a price agreed upon at the time of sale. The underwriters may change from time to time any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers. Applied Genetic Technologies Corporation. Information in such future filings updates and supplements the information provided in this prospectus supplement. The information contained in, or that can be accessed through, our website is not part of this prospectus supplement. In addition, we have a significant number of options and warrants to purchase shares or our Common Stock outstanding. To the extent that any outstanding options or warrants are exercised, or we otherwise issue additional shares of Common Stock in the future, at a price less than the public offering price, there will be further dilution to the investors. We may issue warrants for the purchase of common stock. Hepatitis C. Biohaven Pharmaceutical Holding Company Ltd. Risks Relating to Our Business. Manner of offering. The documents listed below are incorporated by reference into this registration statement:. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects or may render the Company unable to continue operations.

Our Board is empowered, without shareholder approval, to issue a series of preferred stock with dividend, liquidation, conversion, voting or other rights which could dilute the interest of, or impair the voting power of, our common shareholders. While there is a statutory exemption for private placements under Section 4 a 2 of the Securities Act, the absence of the Rule safe harbor under Regulation D could adversely affect our ability to raise necessary financing in the future on terms favorable to us, or at all. The First Republic Corporation of America. Each time that we wish to sell shares of our Common Stock under the equity distribution agreement, we will provide notice to the Agent containing the parameters within which the shares must be sold, which shall at a minimum include the number of shares, the time period during which sales are requested to be made, any limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. The second part consists of a prospectus dated October 10, , included in the registration statement on Form S-3 No. Presently we have cash to last through December If specified by us, the Agent may also sell our Common Stock by any other method permitted by law, including but not limited to in privately negotiated transactions. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. We may need to raise additional capital or otherwise obtain funding through strategic alliances if we initiate clinical trials for new product candidates other than programs currently partnered. In addition, we have a significant number of options and warrants to purchase shares or our Common Stock outstanding. In that case, the trading price of our Common Stock could decline, and you may lose all or part of your investment. In addition, any majority-owned subsidiary of a company on the SRO List would likewise be considered an SRO, including where the company is structured as a holding company. In connection with the sale of the securities, underwriters may receive compensation from us or from purchasers of the securities, for whom they may act as agents, in the form of discounts, concessions or commissions. We have not paid dividends on our common stock since inception and do not plan to pay dividends on our common stock in the foreseeable future.

This relative strength index setting heiken ashi disrupt the Phase 2a study. There are some situations where a financial interest may constitute a prohibited financial interest in an SRO, even if it is not included on the SRO List. In that case, the trading price of our Common Stock could decline, and you may lose all or part of your investment. Additionally, we have developed proprietary targeted in-house chemical libraries of non-nucleoside inhibitors, metal-binding inhibitors, and drug-like fragments. We may offer and sell these securities to trade simulator tool short term trade through one or more underwriters, dealers or agents, or directly to purchasers on a continuous or delayed basis. The Company expects to report a net loss for the year ending December 31, The prospectus supplement for each offering of securities will describe the plan of wealthfront portfolio options etrade rollover ira to roth for that offering. The name of any such underwriter or agent involved in the offer and sale of our securities, the amounts underwritten, and the nature of its obligations to take our securities will be described in the applicable prospectus supplement. Dilution per share to new investors in this offering. This investment involves a high degree of risk. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. Until a holder exercises the warrants to purchase any securities underlying the warrants, the holder will not have any rights as a holder of the underlying securities by virtue of ownership of warrants. We may have agreements with the underwriters, dealers, agents and remarketing firms to indemnify them against certain civil liabilities, including liabilities under the Securities Act, or to contribute with respect to payments that the underwriters, dealers, agents or remarketing firms may be required to make.

If some or all of these goals are not achieved, we may not receive some or all of the milestone payments under the Collaboration Agreement. Under the terms of the Collaboration Agreement, Merck is funding research and development for the program at Cocrystal and Merck, including clinical development at Merck, and Merck is responsible for worldwide commercialization of any products derived from the collaboration. After the close of business on the expiration date, unexercised warrants will be void. If we are unable to continue as a going concern, our stockholders will likely lose all of their investment in the Company. The holders of common stock are entitled to any dividends that may be declared by the Board of Directors out of funds legally available for payment of dividends subject to the prior rights of holders of preferred stock and any contractual restrictions we have against the payment of dividends on common stock. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Prospectus Summary. We hereby incorporate by reference the following information or documents into this prospectus supplement and the accompanying prospectus:. Common Stock outstanding before this offering. To the extent required by Regulation M, the Agents will not engage in any market making activities involving our Common Stock while the offering is ongoing under this prospectus supplement. Exercise of warrants.

One of our goals is treating human and avian bird influenza. Use of Proceeds. The exercise price and number of shares of Common Stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary cash dividend or our recapitalization, reorganization, share reconstruction, amalgamation or consolidation. We or the Agent may suspend the offering of our Common Kraken bitcoin btc trading fee coinbase under the equity distribution agreement upon proper notice and subject to other conditions. In addition, knowledge and experience in the fields of structural biology, and enzymology are required. Also, the SEC maintains an internet site that contains reports, proxy and information statements, and other information that we file electronically with the SEC, including the registration statement. From inception untilour operations were limited to organizing and staffing the Company, acquiring and developing intellectual property rights, developing our technology platform, undertaking basic research on viral replication enzyme targets and conducting preclinical studies for our initial programs. We have not applied for a waiver, and even if we do, the SEC may choose not to grant us a waiver. Corporate Information. Achieving the milestones may be difficult and time-consuming. We may offer and sell these securities to or through one or more underwriters, dealers or agents, or directly to purchasers on a continuous or delayed basis. Unless we inform you otherwise in the applicable prospectus supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment. Social trading automatically copy profit sharing vs stock bonus determine the structures of cocrystals containing the inhibitors bound to the enzyme or protein to guide our design. In addition, the former Biozone Pharmaceuticals, Inc. The occurrence of any of these risks could harm our business. In addition, any majority-owned subsidiary of a company on the SRO List would likewise be considered an SRO, including where the company is structured as a holding company.

We cannot predict the effect, if any, that market sales of shares of our Common Stock or the availability of shares of our Common Stock for sale will have on the market price of our Common Stock prevailing from time to time. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined whether this prospectus is truthful or complete. Requests should be directed to:. However, in order to conduct trials for our other product candidates, we will need to raise additional capital to support our operations or form partnerships, in addition to our existing collaborative alliances, which may give substantial rights to a partner. By concentrating our research and development efforts on viral replication inhibitors, we plan to leverage our infrastructure and expertise in these areas. To the extent this prospectus supplement contains summaries of the documents referred to herein, you are directed to the actual documents for complete information. While we are uncertain as to the amount of future litigation costs, any adverse judgment or settlement is likely to be material. Our drug discovery process is different from traditional, empirical, medicinal chemistry approaches that often require iterative high-throughput compound screening and lengthy hit-to-lead processes. The Company is in partnership discussions for further clinical development of CC Under the equity distribution agreement, the Agent will be entitled to compensation of up to 2. Insofar as indemnification for liabilities arising under the Securities Act of may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, Cocrystal has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. To the extent required by Regulation M, the Agents will not engage in any market making activities involving our Common Stock while the offering is ongoing under this prospectus supplement. This prospectus supplement and the accompanying prospectus do not constitute an offer of, or an invitation to purchase, any shares of Common Stock in any jurisdiction in which such offer or invitation would be unlawful. Our Company.